Exchange: NASDAQ·Updated 02:34 PM EST

IMAB I-Mab - ADR

$0.7898
$0.0017
(0.21%)
Today
EarningsMar 8
Mkt Cap$91.81M
Vol631,604.00

About IMAB

NovaBridge Biosciences operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.
62

Bullish Sentiment

How do you feel about IMAB?

Stocksman45
$IMAB Potential big catalyst at ESMO 2026 this month! Phase 1b results, if same as previous results will de-risk Givastomig and add value to NBP. Second catalyst accelerated Phase III. ESMO 2026 Presentation Details: • Event: European Society for Medical Oncology (ESMO) Congress 2026 • Dates: October 23–27, 2026 • Presentation Date: October 25, 2026 • Location: Madrid, Spain Study & Drug Focus: • Drug: Givastomig (a potential first-in-class Claudin 18.2 × 4-1BB bispecific antibody / Claudin 18.2-Targeted Immuno Amplifier) • Combination Regimen: Givastomig combined with nivolumab and chemotherapy (mFOLFOX6) Program Context: • FDA Status: Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for untreated advanced/metastatic GEA in combination with nivolumab and chemotherapy. • Next Steps: A global, randomized Phase 2 study is underway, with a Phase 3 registrational study under a potential Accelerated Approval Pathway anticipated as early as the end of 2026.
2
Stocksman45
$IMAB On October 28, NovaBridge appointed Chuck Silberstein as CFO. His background includes: - Biotechnology financing. - Capital markets. - Business development. - Corporate strategy. - Healthcare investing. He previously held CFO and business-development positions at other biotech companies. AI considers this a positive management development. Why? NovaBridge is entering a period when it needs to make important capital-allocation decisions: - Financing Givastomig's Phase 3 program. - Advancing VIS-101. - Potentially partnering one or more assets. - Considering strategic transactions. The company specifically highlighted his financing and strategic transaction experience. This could indicate management is preparing for a more sophisticated financing or partnering strategy.
1
Stocksman45
$IMAB NovaBridge scheduled an investor webcast for November 2, 2026, featuring Dr. Samuel J. Klempner, and reported a solid capital position with $190.6 million in cash as of mid-2026 to support late-stage trials. ESMO improves the investment case. The durability of the responses, the selected dose and the apparent tolerability are all encouraging. The results make it easier to argue that Givastomig is a serious registrational candidate rather than merely an interesting early-stage molecule.
1
LabPsycho
$IMAB 5 month range accuracy - Hit the 1.2 today predicted back in May when this was 2 ish.
1
FF355
$IMAB gastritis and 26 discontinuation are real concerns. They have found ways to improve it
GamblingFerret
$IMAB no news today, only showing the updated ESMO data. No details on phase 3 design unfortunately

Advertisement|Remove ads.